Source:http://linkedlifedata.com/resource/pubmed/id/11440287
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
6
|
| pubmed:dateCreated |
2001-7-6
|
| pubmed:abstractText |
Ezetimibe, a selective inhibitor of intestinal cholesterol absorption, is in clinical development for the treatment of hypercholesterolemia. It is rapidly absorbed and glucuronidated in the intestine. The parent compound and its conjugated metabolite undergo enterohepatic recirculation, resulting in multiple peaks in the plasma concentration-time profile.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jun
|
| pubmed:issn |
0149-2918
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
23
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
871-85
|
| pubmed:dateRevised |
2004-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:11440287-Adult,
pubmed-meshheading:11440287-Algorithms,
pubmed-meshheading:11440287-Anticholesteremic Agents,
pubmed-meshheading:11440287-Area Under Curve,
pubmed-meshheading:11440287-Azetidines,
pubmed-meshheading:11440287-Enterohepatic Circulation,
pubmed-meshheading:11440287-Female,
pubmed-meshheading:11440287-Half-Life,
pubmed-meshheading:11440287-Humans,
pubmed-meshheading:11440287-Male,
pubmed-meshheading:11440287-Models, Biological
|
| pubmed:year |
2001
|
| pubmed:articleTitle |
A population pharmacokinetic model that describes multiple peaks due to enterohepatic recirculation of ezetimibe.
|
| pubmed:affiliation |
Schering-Plough Research Institute, Kenilworth, New Jersey 07033, USA. farkad.ezzet@spcorp.com
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial
|